scholarly journals P1471Comparison of three different diuretic treatment strategies in acute decompensated heart failure patients

2017 ◽  
Vol 38 (suppl_1) ◽  
Author(s):  
C. Yayla ◽  
A. Akyel ◽  
U. Canpolat ◽  
K. Gayretli Yayla ◽  
A. Eyiol ◽  
...  
Keyword(s):  
Heart Failure ◽  
Acute Decompensated Heart Failure ◽  
Treatment Strategies ◽  
Decompensated Heart Failure ◽  
Diuretic Treatment ◽  
Heart Failure Patients

Comparison of three diuretic treatment strategies for patients with acute decompensated heart failure

Herz ◽  
2015 ◽  
Vol 40 (8) ◽  
pp. 1115-1120 ◽  
Author(s):  
Çağrı Yayla ◽  
Ahmet Akyel ◽  
Uğur Canpolat ◽  
Kadriye Gayretli Yayla ◽  
Azmi Eyiol ◽  
...  
Keyword(s):  
Heart Failure ◽  
Acute Decompensated Heart Failure ◽  
Treatment Strategies ◽  
Decompensated Heart Failure ◽  
Diuretic Treatment

scholarly journals Heart Rate at Discharge in Patients with Acute Decompensated Heart Failure is a Predictor of Mortality

2020 ◽  
Author(s):  
Thomas Vollmert ◽  
Martin Hellmich ◽  
Natig Gassanov ◽  
Fikret Er ◽  
Seyrani Yücel ◽  
...  
Keyword(s):  
Heart Failure ◽  
Heart Rate ◽  
Chronic Heart Failure ◽  
Acute Decompensated Heart Failure ◽  
Survival Rates ◽  
Treatment Strategies ◽  
Decompensated Heart Failure ◽  
University Hospital ◽  
Heart Failure Patients ◽  
Prediction Of Mortality

Abstract Aims Heart failure is a syndrome with increasing prevalence in concordance with the aging population and better survival rates from myocardial infarction. Morbidity and mortality are high in chronic heart failure patients, particularly in those with hospital admission for acute decompensation. Several risk stratification tools and score systems have been established to predict mortality in chronic heart failure patients. However, identification of patients at risk with easy obtainable clinical factors that can predict mortality in acute decompensated heart failure (ADHF) are needed to optimize the care-path. Methods and Results We retrospectively analyzed electronic medical records of 78 patients with HFrEF and HFmrEF who were hospitalized with ADHF in the Heart Center of the University Hospital Cologne in the year 2011 and discharged from the ward after successful treatment. 37.6±16.4 months after index hospitalization 30 (38,5%) patients had died. This mortality rate correlated well with the calculated predicted survival with the Seattle Heart Failure Model (SHFM) for each individual patient. In our cohort, we identified elevated heart rate at discharge as an independent predictor for mortality (p=0.016). The mean heart rate at discharge was lower in survived patients compared to patients who died (72.5±11.9 bpm vs. 79.1±11.2 bpm. Heart rate of 77 bpm or higher was associated with an almost doubled mortality risk (p=0.015). Heart rate elevation of 5 bpm was associated with an increase of mortality of 25% (p=0.022).Conclusions Patients hospitalized for ADHF seem to have a better prognosis, when heart rate at discharge is <77 bpm. Heart rate at discharge is an easily obtainable biomarker for risk prediction of mortality in HFrEF and HFmrEF patients treated for acute cardiac decompensation. Taking into account this parameter could be useful for guiding treatment strategies in these high-risk patients. Prospective data for validation of this biomarker and specific intervention is needed.

scholarly journals Heart rate at discharge in patients with acute decompensated heart failure is a predictor of mortality

2020 ◽  
Vol 25 (1) ◽  
Author(s):  
Thomas Vollmert ◽  
Martin Hellmich ◽  
Natig Gassanov ◽  
Fikret Er ◽  
Seyrani Yücel ◽  
...  
Keyword(s):  
Heart Failure ◽  
Heart Rate ◽  
Chronic Heart Failure ◽  
Acute Decompensated Heart Failure ◽  
Survival Rates ◽  
Treatment Strategies ◽  
Decompensated Heart Failure ◽  
University Hospital ◽  
Heart Failure Patients ◽  
Prediction Of Mortality

Abstract Aims Heart failure is a syndrome with increasing prevalence in concordance with the aging population and better survival rates from myocardial infarction. Morbidity and mortality are high in chronic heart failure patients, particularly in those with hospital admission for acute decompensation. Several risk stratification tools and score systems have been established to predict mortality in chronic heart failure patients. However, identification of patients at risk with easy obtainable clinical factors that can predict mortality in acute decompensated heart failure (ADHF) are needed to optimize the care-path. Methods and results We retrospectively analyzed electronic medical records of 78 patients with HFrEF and HFmrEF who were hospitalized with ADHF in the Heart Center of the University Hospital Cologne in the year 2011 and discharged from the ward after successful treatment. 37.6 ± 16.4 months after index hospitalization 30 (38.5%) patients had died. This mortality rate correlated well with the calculated predicted survival with the Seattle Heart Failure Model (SHFM) for each individual patient. In our cohort, we identified elevated heart rate at discharge as an independent predictor for mortality (p = 0.016). The mean heart rate at discharge was lower in survived patients compared to patients who died (72.5 ± 11.9 vs. 79.1 ± 11.2 bpm. Heart rate of 77 bpm or higher was associated with an almost doubled mortality risk (p = 0.015). Heart rate elevation of 5 bpm was associated with an increase of mortality of 25% (p = 0.022). Conclusions Patients hospitalized for ADHF seem to have a better prognosis, when heart rate at discharge is < 77 bpm. Heart rate at discharge is an easily obtainable biomarker for risk prediction of mortality in HFrEF and HFmrEF patients treated for acute cardiac decompensation. Taking into account this parameter could be useful for guiding treatment strategies in these high-risk patients. Prospective data for validation of this biomarker and specific intervention are needed.

scholarly journals Heart Rate at Discharge in Patients with Acute Decompensated Heart Failure is a Predictor of Mortality

2020 ◽  
Author(s):  
Thomas Vollmert ◽  
Martin Hellmich ◽  
Natig Gassanov ◽  
Fikret Er ◽  
Seyrani Yücel ◽  
...  
Keyword(s):  
Heart Failure ◽  
Heart Rate ◽  
Chronic Heart Failure ◽  
Acute Decompensated Heart Failure ◽  
Survival Rates ◽  
Treatment Strategies ◽  
Decompensated Heart Failure ◽  
University Hospital ◽  
Heart Failure Patients ◽  
Prediction Of Mortality

Abstract Aims Heart failure is a syndrome with increasing prevalence in concordance with the aging population and better survival rates from myocardial infarction. Morbidity and mortality are high in chronic heart failure patients, particularly in those with hospital admission for acute decompensation. Several risk stratification tools and score systems have been established to predict mortality in chronic heart failure patients. However, identification of patients at risk with easy obtainable clinical factors that can predict mortality in acute decompensated heart failure (ADHF) are needed to optimize the care-path. Methods and Results We retrospectively analyzed electronic medical records of 78 patients with HFrEF and HFmrEF who were hospitalized with ADHF in the Heart Center of the University Hospital Cologne in the year 2011 and discharged from the ward after successful treatment. 37.6±16.4 months after index hospitalization 30 (38,5%) patients had died. This mortality rate correlated well with the calculated predicted survival with the Seattle Heart Failure Model (SHFM) for each individual patient. In our cohort, we identified elevated heart rate at discharge as an independent predictor for mortality (p=0.016). The mean heart rate at discharge was lower in survived patients compared to patients who died (72.5±11.9 bpm vs. 79.1±11.2 bpm. Heart rate of 77 bpm or higher was associated with an almost doubled mortality risk (p=0.015). Heart rate elevation of 5 bpm was associated with an increase of mortality of 25% (p=0.022).Conclusions Patients hospitalized for ADHF seem to have a better prognosis, when heart rate at discharge is <77 bpm. Heart rate at discharge is an easily obtainable biomarker for risk prediction of mortality in HFrEF and HFmrEF patients treated for acute cardiac decompensation. Taking into account this parameter could be useful for guiding treatment strategies in these high-risk patients. Prospective data for validation of this biomarker and specific intervention is needed.

scholarly journals Effect of Carperitide on Plasma Adiponectin Levels in Acute Decompensated Heart Failure Patients With Diabetes Mellitus

2009 ◽  
Vol 73 (12) ◽  
pp. 2264-2269 ◽  
Author(s):  
Masayuki Yamaji ◽  
Takayoshi Tsutamoto ◽  
Toshinari Tanaka ◽  
Chiho Kawahara ◽  
Keizo Nishiyama ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Heart Failure ◽  
Acute Decompensated Heart Failure ◽  
Decompensated Heart Failure ◽  
Plasma Adiponectin ◽  
Heart Failure Patients ◽  
Patients With Diabetes

scholarly journals Noninvasive Ventilation Outcomes in 2,430 Acute Decompensated Heart Failure Patients: An ADHERE Registry Analysis

2008 ◽  
Vol 15 (4) ◽  
pp. 355-362 ◽  
Author(s):  
Thomas A. Tallman ◽  
W. Frank Peacock ◽  
Charles L. Emerman ◽  
Margarita Lopatin ◽  
Jamie Z. Blicker ◽  
...  
Keyword(s):  
Heart Failure ◽  
Noninvasive Ventilation ◽  
Acute Decompensated Heart Failure ◽  
Decompensated Heart Failure ◽  
Heart Failure Patients ◽  
Registry Analysis

Short-term effects of low-dose tolvaptan in acute decompensated heart failure patients with severe aortic stenosis: the LOHAS registry

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
Y Watanabe ◽  
Y Nara ◽  
H Hioki ◽  
H Kawashima ◽  
A Kataoka ◽  
...  
Keyword(s):  
Heart Failure ◽  
Aortic Stenosis ◽  
Low Dose ◽  
Acute Decompensated Heart Failure ◽  
Severe Aortic Stenosis ◽  
Decompensated Heart Failure ◽  
Funding Source ◽  
Short Term ◽  
Heart Failure Patients ◽  
Short Term Effects

Abstract Background Tolvaptan exerts potent diuretic effects in heart failure patients without hemodynamic instability. Nonetheless, its clinical efficacy for acute decompensated heart failure (ADHF) due to severe aortic stenosis (AS) remains unclear. This study aimed to evaluate the short-term effects of tolvaptan in ADHF patients with severe AS. Methods The LOw-Dose Tolvaptan (7.5 mg) in Decompensated Heart Failure Patients with Severe Aortic Stenosis (LOHAS) registry is a multicenter (7 centers) prospective registry that assessed the short-term effects of tolvaptan in subjects hospitalized for ADHF with severe AS. A total of 59 subjects were enrolled between September 2014 and December 2017. The primary endpoints were changes in body weight and fluid balance measured daily from baseline up to 4 days. Results The median [interquartile range] patient age and aortic valve area were 85.0 [81.0–89.0] years and 0.58 [0.42–0.74] cm2, respectively. Body weight continuously decreased, and fluid balance was maintained from baseline to day 4 (p&lt;0.001, p=0.194, respectively). Median serum B-type natriuretic peptide concentration significantly decreased from 910.5 to 740.0 pg/mL by day 4 (p=0.002). However, systolic blood pressure and heart rate were non-significantly changed (p=0.250, p=0.656, respectively). Hypernatremia (&gt;150 mEq/L) and worsening renal function occurred in 2 (3.4%) and 4 (6.8%) patients, respectively. Conclusions Short-term treatment with low-dose tolvaptan is safe and effective, providing stable hemodynamic parameters in patients with ADHF and severe AS. Funding Acknowledgement Type of funding source: Private company. Main funding source(s): This research was supported by Otsuka Pharmaceutical Co., Ltd.

scholarly journals Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers

2010 ◽  
Vol 12 (4) ◽  
pp. 404-410 ◽  
Author(s):  
Claes-Håkan Bergh ◽  
Bert Andersson ◽  
Ulf Dahlström ◽  
Kolbjorn Forfang ◽  
Matti Kivikko ◽  
...  
Keyword(s):  
Heart Failure ◽  
Acute Decompensated Heart Failure ◽  
Beta Blockers ◽  
Decompensated Heart Failure ◽  
Heart Failure Patients
Sign in / Sign up

Export Citation Format

Share Document